PfSPZ Malaria Vaccine

Novitasari, Dwi Ayu Fani (2022) PfSPZ Malaria Vaccine. International Journal of Science and Research (IJSR), 11 (3). pp. 76-77. ISSN 2319-7064

PDF Dwi Ayu Fani_PfSPZ Malaria Vaccine.pdf Download (124kB)

Abstract

Malaria is a disease caused by parasites. As we know that parasites have 3 life cycles while it’s on the human host: pre-erythrocytes phase, blood-stage phase, and transmissionblocking phase. As for now, the medicine for malaria disease is artemisin combination therapy which is going to be resistant, so people try to develop a vaccine for malaria to meet the goal of malaria eradication. One of the vaccines developed is RTS,S/AS01. RTS,S/AS01 is pre-erythrocytic vaccine that confers efficacy against controlled human malaria infection in about 22% in healthy malaria 5 months after vaccination. In clinical trial phase 3, RTS,S/AS01 was 26% in young infants and 36% in children (Ishizuka et al., 2016). Eradication of malaria needs vaccine protection of more than 80% and has protective efficacy for more than 6 months. Therefore, the development of a malaria vaccine is still needed. Another malaria vaccine is PfSPZ. PfSPZ is pre-erythrocytic stage vaccine similar to RTS,S/AS01. It is whole attenuated sporozoite Plasmodium falciparum.

Item Type:	Article
Uncontrolled Keywords:	vaccine, malaria, PfSPZ
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Pharmacy > Department of Pharmacy
Depositing User:	Dwi Ayu Fani Novitasari
Date Deposited:	21 Mar 2022 02:06
Last Modified:	29 Mar 2022 03:04
URI:	http://repository.ubaya.ac.id/id/eprint/41583

Actions (login required)

View Item